Vyleesi HSA/FSA Eligibility and Submission: How to Pay Less for Bremelanotide

Is Vyleesi HSA/FSA Eligible?

Yes. Vyleesi (bremelanotide) is a legal prescription medication approved by the FDA for a defined medical condition, hypoactive sexual desire disorder (HSDD). Any prescription drug that is legally prescribed for a medical purpose qualifies as a reimbursable medical expense under IRS Publication 502. IRS Publication 502 states that the cost of prescription medications is deductible and, by extension, payable from HSA and FSA accounts.

Bremelanotide received FDA approval on June 21, 2019, for the treatment of premenopausal women with acquired, generalized HSDD. That approval is documented in the FDA drug approval package.

Why HSDD Qualifies as a Medical Condition

HSDD is classified in the DSM-5 (as part of female sexual interest/arousal disorder) and causes clinically significant distress. The FDA review of bremelanotide was grounded in randomized controlled trial evidence showing statistically meaningful improvements in desire and reductions in distress. Because the underlying diagnosis is a recognized medical condition and not a lifestyle choice, insurance payers and IRS guidance treat the drug the same as any other prescription medication. PubMed PMID 30894121 summarizes the clinical pharmacology basis for approval.

What IRS Publication 502 Actually Says

IRS Publication 502 covers "amounts paid for prescribed drugs and insulin." A prescribed drug is one that requires a prescription under federal or state law. Vyleesi meets this definition. The cost of the medication itself, including dispensing fees charged at the pharmacy, counts toward the eligible expense. You cannot, however, use HSA or FSA funds for shipping upgrades, convenience fees, or membership fees on a digital pharmacy platform, only the drug cost and mandatory dispensing fee. IRS Rev. Proc. 2024-25 sets the 2025 HSA limits that govern how much you can accumulate to cover these expenses.

How to Submit a Vyleesi Claim to Your HSA or FSA

Submitting a claim is straightforward when you have the right documentation. The process differs slightly between HSA accounts (which are self-directed) and FSA accounts (which require employer plan approval).

Step 1: Collect Your Documentation

You need three documents for a clean submission:

• Itemized pharmacy receipt showing the drug name (bremelanotide or Vyleesi), National Drug Code (NDC), quantity dispensed, date of service, and amount paid.
• Prescription record or prescriber information confirming this is a legally prescribed medication. Most pharmacy printouts include this automatically.
• Letter of Medical Necessity (LMN) only if your specific plan administrator requires one. Not all plans do, but having your prescribing clinician prepare a brief LMN that references the HSDD diagnosis (ICD-10 code F52.0) can prevent denials.

The FDA prescribing information for Vyleesi lists the indication precisely, which your clinician can quote in an LMN.

Step 2: Submit Through Your Plan's Portal or App

Most HSA custodians (Fidelity, HSA Bank, HealthEquity, Optum Bank) and FSA administrators allow digital claim submission. Upload a PDF or photo of your itemized receipt. The claim category to select is "prescription drugs." Processing typically takes 5 to 10 business days.

If your HSA-linked debit card was used directly at the pharmacy, no claim submission is needed, the transaction records automatically. If you paid out of pocket, submit for reimbursement within your plan's claim filing deadline, which for FSAs is often 90 days after the plan year ends or after the grace period closes.

Step 3: Respond to Requests for Additional Documentation

Some FSA administrators flag medications they do not immediately recognize. If your claim is pended, submit the LMN and a printout of the FDA approval summary as supporting evidence. Claims for approved prescription drugs cannot be denied on the grounds that the condition is not serious, IRS rules do not stratify conditions by severity.

What Vyleesi Costs Without Insurance

Bremelanotide is sold as a single-use auto-injector pre-filled with 1.75 mg. The wholesale acquisition cost in 2025 is approximately $820 per injector. Most patients use one injector per sexual encounter and are not expected to use more than one per 24-hour period, per the FDA-approved label.

Insurance Coverage Rates

Commercial insurance coverage for Vyleesi varies widely. A 2020 analysis in the Journal of Sexual Medicine noted that access barriers for HSDD pharmacotherapy remained significant after FDA approval, with formulary placement inconsistent across payers. PMID 33272892 examined real-world prescription patterns after the approvals of both flibanserin and bremelanotide and found that insurance denials and prior authorization requirements limited uptake substantially.

When insurance does cover Vyleesi, specialty tier copays of $50 to $200 per fill are common. Many plans require prior authorization confirming the HSDD diagnosis, documentation of distress, and sometimes a trial of non-pharmacological therapy first.

The Role of HSA/FSA When Insurance Denies

When a prior authorization is denied or when a patient is uninsured, HSA and FSA funds become the most tax-efficient payment method available. Paying with pre-tax dollars through an HSA reduces the effective cost by your marginal tax rate. For someone in the 22% federal bracket, an $820 injector costs roughly $640 in pre-tax dollars, not accounting for any applicable state tax savings. IRS Publication 969 explains the tax treatment of HSA distributions in full.

Manufacturer Savings Programs and How to Stack Them With HSA/FSA

The Palatin/AMAG Savings Card

Palatin Technologies licensed Vyleesi to AMAG Pharmaceuticals (subsequently acquired by Covis Pharma) for U.S. Commercialization. A co-pay savings card program has been available for commercially insured patients. Under the program terms current as of early 2026, eligible patients with commercial insurance may pay as little as $0 for a fill. Patients on Medicare, Medicaid, or other federal programs are not eligible for manufacturer co-pay cards, per federal anti-kickback statute guidance. FDA guidance on patient assistance programs explains the regulatory framework around these offers.

To access the savings card, visit the official Vyleesi patient support website or ask your pharmacist to run the card through as a secondary payer after your primary insurance.

Can You Combine a Manufacturer Savings Card With HSA/FSA?

The IRS position here is specific. If a manufacturer coupon or savings card reduces your out-of-pocket cost to zero, there is no remaining expense to submit to your HSA or FSA. You can only submit the amount you actually paid. Submitting the full retail price when a coupon covered it would be a prohibited transaction under IRS Notice 2004-50, which governs qualified medical expenses and HSA distributions.

If the savings card reduces your cost from $820 to $50, you may submit the $50 co-pay to your HSA or FSA. Document the amount you personally paid, not the pre-coupon price.

GoodRx and Other Discount Platforms

GoodRx, RxSaver, and similar platforms negotiate cash-pay prices at participating pharmacies. Bremelanotide pricing through these platforms fluctuates but may be meaningfully below WAC at select pharmacies. The critical limitation: IRS Notice 2023-37 and earlier guidance clarify that you cannot use HSA funds to pay for a drug and simultaneously use a GoodRx coupon through a separate payment mechanism on the same transaction. Pay with your HSA debit card and supply the GoodRx discount code as the pricing method at the pharmacy counter. The pharmacy will apply the lower negotiated rate, and your HSA card will be charged only that lower amount. IRS Notice 2023-37 addressed HSA interactions with direct primary care and telehealth but reinforces the principle that HSA reimbursements must match actual amounts paid.

Clinical Background: What the Evidence Says About Bremelanotide

Understanding why this drug is prescribed helps contextualize the access challenges and why out-of-pocket cost management matters for real patients.

Mechanism of Action

Bremelanotide is a melanocortin receptor agonist, specifically activating MC1R, MC3R, MC4R, and MC5R. Its central nervous system activity, particularly at MC4R in the hypothalamus, is thought to modulate sexual desire pathways. This distinguishes it mechanistically from flibanserin (Addyi), which acts on serotonin receptors. The bremelanotide FDA pharmacology review details the receptor binding profile and CNS pharmacodynamics.

RECONNECT Trial Results

The FDA approval was supported by two Phase 3 randomized controlled trials called RECONNECT (Studies 301 and 302, combined N=1,267 premenopausal women with HSDD). Both trials measured two co-primary endpoints: change from baseline in the Female Sexual Function Index desire domain score and change in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 distress score.

In the pooled analysis, bremelanotide 1.75 mg produced a statistically significant improvement in both endpoints versus placebo. The mean change in satisfying sexual events per month was 0.5 greater than placebo (P<0.001). PMID 30894121 reports the full RECONNECT efficacy and safety data. PMID 31348829 provides the long-term safety extension analysis.

Adverse Effects Relevant to Treatment Planning

Nausea was the most common adverse effect, reported in approximately 40% of patients in RECONNECT, though it was transient in most cases. Transient blood pressure increases of approximately 6 mmHg systolic were observed within 12 hours of dosing. The label carries a warning against use in patients with known cardiovascular disease or uncontrolled hypertension. PMID 32353235 examined cardiovascular safety monitoring data from the RECONNECT program. Patients and prescribers reviewing this profile should consult the full prescribing information before initiating therapy.

HSDD Diagnosis and the Path to a Prescription

You cannot obtain Vyleesi without a prescription, and obtaining a prescription requires a clinical evaluation confirming the HSDD diagnosis. This section matters for HSA/FSA planning because the evaluation itself may also be an eligible expense.

Who Can Diagnose HSDD

Any licensed physician, nurse practitioner, or physician assistant can diagnose HSDD. The diagnosis requires that low sexual desire causes marked distress and cannot be better explained by another psychiatric condition, relationship distress, or a medical condition causing low desire secondarily. The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction (academic.oup.com/jcem) recommends a biopsychosocial assessment including hormone panel review before pharmacotherapy.

Telehealth Prescribing

Several telehealth platforms now offer HSDD evaluation and can prescribe Vyleesi if appropriate. The telehealth visit copay or fee is itself an HSA/FSA-eligible expense under IRS Publication 502. The Consolidated Appropriations Act of 2023 extended telehealth HSA-compatibility rules through 2024; as of the 2026 plan year, consult IRS Notice 2024-75 for the current telehealth HSA safe harbor status.

Laboratory Tests as HSA/FSA Expenses

Before prescribing bremelanotide, many clinicians order a hormone panel (FSH, LH, estradiol, testosterone, TSH, prolactin) to rule out secondary causes of low desire. Each of these laboratory tests is an HSA/FSA-eligible medical expense. Combining the lab costs, the telehealth visit, and the medication into a single HSA reimbursement submission is permitted and can result in substantial tax savings over a plan year.

Practical Cost-Reduction Checklist for Vyleesi Patients

The following decision path reflects the HealthRX clinical access team's recommended sequence for minimizing Vyleesi out-of-pocket cost while staying compliant with IRS and plan rules.

Step 1: Check your insurance formulary. Log into your insurer's portal and search for bremelanotide or Vyleesi. Note the tier, co-pay, and whether prior authorization is required.

Step 2: Submit prior authorization if required. Your prescriber submits the PA with ICD-10 F52.0 (female sexual interest/arousal disorder), clinical notes documenting distress, and, if requested, documentation of prior non-pharmacological interventions.

Step 3: Apply for the manufacturer savings card. If you have commercial insurance, apply at the Vyleesi patient support portal before your first fill. Even if insurance covers part of the cost, the card may reduce your co-pay further.

Step 4: Compare cash-pay prices. If insurance denies and you lack a savings card option, compare GoodRx prices across pharmacies in your area. Prices vary by up to 30% across pharmacy chains for specialty medications.

Step 5: Pay with HSA/FSA funds. Use your HSA debit card or submit for FSA reimbursement with your itemized receipt. Record the exact amount you paid after any coupon or discount.

Step 6: Consider a mail-order or specialty pharmacy. Some specialty pharmacies offer 90-day supplies at a per-unit price modestly below 30-day retail pricing. Confirm that your HSA/FSA plan accepts mail-order pharmacy receipts, which they generally do under IRS Publication 502.

HSA vs. FSA: Which Is Better for Vyleesi?

Both account types cover Vyleesi. The choice between them depends on your employment situation and how predictably you use the medication.

HSA Advantages

HSA funds roll over indefinitely. If you are enrolled in a qualifying high-deductible health plan (HDHP), you can build a balance over multiple years to cover a higher-cost specialty medication. For 2025, the minimum HDHP deductible is $1,650 for self-only coverage per IRS Rev. Proc. 2024-25. HSA accounts also earn interest and can be invested, making them a tax-advantaged savings vehicle beyond their immediate pharmaceutical use.

FSA Advantages

FSA contributions reduce taxable wages in the year of contribution regardless of HDHP enrollment. The $3,300 annual limit for 2025 can cover approximately four Vyleesi injectors at list price. FSA plans may offer a grace period of up to 2.5 months or a $660 rollover (plan-specific). Check your Summary Plan Description for your specific carryover terms. IRS Notice 2024-80 sets the 2025 FSA limits.

Which to Use First

If you have both an HSA and a health FSA in the same year, IRS rules treat a general-purpose health FSA as disqualifying for HSA contributions in most circumstances. A limited-purpose FSA (covering only dental and vision) does not disqualify HSA contributions. Discuss the interaction with your benefits administrator before enrolling in both.

Frequently Asked Questions